Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01980992
Other study ID # GCO 11-0197
Secondary ID FAI001
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date October 2013
Est. completion date April 13, 2017

Study information

Verified date August 2020
Source Icahn School of Medicine at Mount Sinai
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is being done to learn about the medical effects, the safety, and the immunologic effects of Wheat Oral Immunotherapy (OIT) treatment. The goal of the study is to find out whether subjects can develop the ability to eat wheat (the food allergen) regularly without allergic symptoms after stopping the study treatment.


Description:

Food allergy affects 6-8 percent of children in the United States. Wheat is one of the eight most common foods inducing allergic reactions in the US. Current treatment for food allergy is complete avoidance of the food and to carry antihistamines and self-injectable epinephrine if an accidental reaction occurs. However, accidental exposure to allergens in processed foods may be difficult to avoid. Currently, several therapeutic strategies are being investigated to prevent and treat food allergies. Since immunotherapy injections for food allergy are associated with a high rate of allergic reactions, alternate approaches to treatment are needed. Oral (by mouth) immunotherapy (OIT) is one approach that has been tried in some studies in the treatment of food allergies. The intent of the study is to examine the clinical effects and safety of wheat OIT. This study will last 2 years. All eligible subjects will receive a wheat oral food challenge (OFC). Those who react to 1923mg or less of vital wheat gluten will be randomized to Wheat OIT or a placebo. All eligible and enrolled subjects will have a 1-year and 2-year OFC. Placebo subjects will crossover to Wheat OIT at the 1-year time point. At selected visits, blood and urine collection, physical examination, prick skin tests, and atopic dermatitis and asthma evaluations will occur.


Recruitment information / eligibility

Status Completed
Enrollment 46
Est. completion date April 13, 2017
Est. primary completion date November 2015
Accepts healthy volunteers No
Gender All
Age group 4 Years to 30 Years
Eligibility Inclusion Criteria:

- Age 4-30 years either sex, any race, any ethnicity

- Positive Prick Skin Test to wheat greater than 3mm compared to control and/or a wheat specific IgE >= 0.35 kUA/L

- Positive baseline challenge to wheat (<= 1923 mg of vital wheat gluten)

- Written informed consent from subject and/or parent/guardian

- Written assent from all subjects as appropriate

- All females of child bearing age must be using appropriate birth control

Exclusion Criteria:

- History of anaphylaxis to wheat resulting in hypotension, neurological compromise or mechanical ventilation

- Known allergy to corn

- Known celiac disease

- Chronic disease (other than asthma, atopic dermatitis, rhinitis) requiring therapy (e.g., heart disease, diabetes)

- Active eosinophilic gastrointestinal disease in the past two years

- Participation in any interventional study for the treatment of food allergy in the past 6 months

- Subject is on "build-up phase" of immunotherapy (i.e., has not reached maintenance dosing). Subjects tolerating maintenance allergen immunotherapy can be enrolled.

- Severe asthma, uncontrolled mild or moderate asthma. More information on this criterion can be found in the protocol.

- A burst of oral, IM or IV steroids of more than 2 days for an indication other than asthma in the past 1 month

- Inability to discontinue antihistamines for initial day escalation, skin testing or OFC

- Use of omalizumab or other non-traditional forms of allergen immunotherapy or immunomodulator therapy (not including corticosteroids) or biologic therapy within the past year

- Use of beta-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB) or calcium channel blockers

- Use of investigational drug within 90 days or plan to use investigational drug during the study period

- Pregnancy or lactation

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Wheat OIT
Vital Wheat Gluten dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.

Locations

Country Name City State
United States Johns Hopkins University School of Medicine Baltimore Maryland
United States Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois
United States Icahn School of Medicine at Mount Sinai New York New York
United States Stanford University School of Medicine Stanford California

Sponsors (1)

Lead Sponsor Collaborator
Hugh A Sampson, MD

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The Percentage of Desensitized Participants as Measured by the Ability to Consume at Least 4443 mg of Wheat Protein During a 7443 mg Wheat Protein Oral Food Challenge (OFC) Performed 1 Year After Initiating Treatment. Determine in wheat allergic children, whether relative to placebo, daily oral administration of Vital Wheat Gluten escalated to a maximum of 2035 mg/day of Vital Wheat Gluten increases desensitization as measured by consuming without dose limiting symptoms 4443 mg of wheat protein on a 7443 mg wheat protein OFC performed 1 year after initiating treatment. 1 Year
Secondary Number of Subjects Who Successfully Consume a Wheat Protein Oral Food Challenge The number of subjects who successfully consume a 7443 mg wheat protein oral food challenge (OFC) 8-10 weeks after therapy discontinuation and after passing the 7443 mg wheat protein OFC at the 2 year time point.This OFC will only be administered to subjects in the initial active treatment group. 8 to 10 weeks after passing the 2 Year OFC
Secondary Number of Subjects Who Achieve the Targeted Maintenance Dose of Wheat OIT The number of subjects who achieve the targeted maintenance dose of wheat OIT during the desensitization phase of the study. For Wheat OIT group, reached target dose of 2035 mg wheat powder/1445 mg wheat protein. For placebo group, reached target dose of 2035 mg placebo powder. 44 Weeks
Secondary Number of Subjects That Achieve Desensitization in the Placebo Cross Over Group The number of subjects that achieve desensitization in the placebo cross over group after 1 year of dosing. Able to consume at least 4443 mg wheat protein on the Week 52 Crossover OFC (4443 mg wheat protein is the amount that was used for the primary endpoint). 2 Years
Secondary Incidence of All Serious Adverse Events During the Study. 1 year and 2 Years
See also
  Status Clinical Trial Phase
Completed NCT04100122 - Luminex-based Assay to Identify Major IgE-binding Episode Among IgE-mediated Wheat-allergic Patient
Terminated NCT02341040 - Evaluation of Potential Allergenicity of New Wheat Varieties
Completed NCT01801748 - The Natural History of Wheat Hypersensitivity in Thai Children N/A
Recruiting NCT06069492 - Randomized Controlled Trial for Wheat Oral Immunotherapy N/A
Completed NCT01070368 - Accuracy Of Skin Prick Test Using In-house Wheat Extract For The Diagnosis Of IgE-mediated Wheat Allergy: A Pilot Study N/A
Terminated NCT04013763 - Outcome of Specific IgE Level in Children With IgE-mediated Wheat Allergy After Stop Using Wheat Containing Skin Care N/A
Recruiting NCT03352193 - Specific Oral Tolerance Induction (SOTI) to Children With IgE-mediated Wheat Allergy
Completed NCT01755884 - Oral Desensitization to Wheat in School Aged Children N/A
Completed NCT03487315 - Major Allergen in Wheat Anaphylaxis in Thai Population N/A